TW200720440A - Method - Google Patents

Method

Info

Publication number
TW200720440A
TW200720440A TW095111374A TW95111374A TW200720440A TW 200720440 A TW200720440 A TW 200720440A TW 095111374 A TW095111374 A TW 095111374A TW 95111374 A TW95111374 A TW 95111374A TW 200720440 A TW200720440 A TW 200720440A
Authority
TW
Taiwan
Prior art keywords
patient
treatment
erbb receptor
likelihood
receptor drug
Prior art date
Application number
TW095111374A
Other languages
Chinese (zh)
Inventor
Gillian Ellison
Ruth Eleanor March
Alan Wookey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200720440A publication Critical patent/TW200720440A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The invention relates to a method for predicting the likelihood that a patient who is a candidate for treatment with an erbB receptor drug will respond to said treatment, comprising determining the sequence of EGFR in a tumour sample from the patient, whereby to predict an increased likelihood of response to the erbB receptor drug.
TW095111374A 2005-04-01 2006-03-31 Method TW200720440A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0506670A GB0506670D0 (en) 2005-04-01 2005-04-01 Method

Publications (1)

Publication Number Publication Date
TW200720440A true TW200720440A (en) 2007-06-01

Family

ID=34586567

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095111374A TW200720440A (en) 2005-04-01 2006-03-31 Method

Country Status (3)

Country Link
GB (1) GB0506670D0 (en)
TW (1) TW200720440A (en)
WO (1) WO2006103421A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088885A2 (en) * 2007-01-18 2008-07-24 Creighton University Epidermal growth factor receptor mutations and methods of use
WO2016055380A1 (en) * 2014-10-09 2016-04-14 Roche Diagnostics Gmbh Mutations in the epidermal growth factor receptor kinase domain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480200B (en) * 2004-03-31 2017-12-29 综合医院公司 Determine method of the cancer to EGF-R ELISA magnetic target therapy reactivity
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc Egfr mutations
TW200617396A (en) * 2004-10-06 2006-06-01 Astrazeneca Ab Method

Also Published As

Publication number Publication date
GB0506670D0 (en) 2005-05-11
WO2006103421A3 (en) 2007-03-22
WO2006103421A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
NL301089I2 (en) imlifidase
MX2007006529A (en) Selecting patients for therapy with a her inhibitor.
TW200714716A (en) Method
WO2008019375A3 (en) Proteomic patterns of cancer prognostic and predictive signatures
EA200971079A1 (en) GENETIC OPTIONS IN CHR5P12 AND 10Q26 AS MARKERS FOR RISK ASSESSMENT, DIAGNOSIS, PREDICTION AND TREATMENT OF BREAST
PL2733493T3 (en) An in-vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
EA200701979A1 (en) METHOD FOR OBTAINING OPIOID MODULATORS
MX358541B (en) Methods for predicting risk of developing hypertension.
EA201170636A1 (en) Antagonists of toll-like receptor 3
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
BR112012001171A2 (en) selection method. evolution and expression of an antibody fragment or antibody, methods of evolution and expression of an antibody and a protein, method of evolution and manufacture of a protein, method of evolution for enhanced expression and manufacture of a protein, method for identifying and produce a protein, and method of evolution of a protein.
WO2012141844A3 (en) Methods predicting risk of an adverse clinical outcome
MX2020010947A (en) Methods of treating alzheimer's disease.
PL1836500T3 (en) METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
CY1112288T1 (en) Cancer treatment with antibodies against IL-1A
ATE553778T1 (en) ANTIBODIES SPECIFIC TO HUMAN HEPCIDIN
MX356866B (en) P53 biomarkers.
MX2009002471A (en) Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase.
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
TW200720440A (en) Method
TW200617396A (en) Method
ATE521893T1 (en) P66-SHC AS A PREDICTIVE MARKER IN CANCER TREATMENT
GB201017228D0 (en) Drug response markers
UA96623U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT